Progyny (PGNY) Stock Forecast & Price Target

Progyny is viewed favorably because its integrated fertility and family-building platform combines Smart Cycles, a differentiated clinician network, and high-touch care advocates to deliver superior clinical outcomes, stronger member experience, and measurable ROI for employers. The company’s fundamentals are reinforced by best-in-class retention above 99%, winning more than 50% of evaluated deals, approximately 7 million covered lives served out of a roughly 105 million self-insured market, and a company-estimated $8 bln TAM that still looks underpenetrated. Recent 1Q26 results and guidance lift further support the bullish case, with revenue and EBITDA topping consensus, 595 active clients, 7.2M average membership, and 2026 revenue guidance raised to $1.365B-$1.405B alongside EBITDA guidance of $232M-$244M.

Progyny is facing a negative setup because elevated attrition, utilization pressure, slower-than-expected new solution revenue, and a potential economic downturn could all weigh on membership growth and employer adoption of fertility benefits. Its outlook is further clouded by political uncertainty around reproductive rights and competition from traditional insurers and start-ups, while the 2022 broad-based grant added stock-based compensation expense. Although covered lives remain the long-term growth engine and the company targets about 1 million new covered lives annually on a base of roughly 6.9 million eligible members, these secular tailwinds may not offset near-term execution and demand risks.